NBTX Earnings

NBTX reported its earnings on , showcasing a revenue of undefined against an estimate of undefined, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NBTX's earnings announcement on , the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, NBTX's stock price tends to shift by an average of 0% in the 10 days leading up to earnings and 0% in the 10 days following, providing insight into potential market.

For , analysts estimate NBTX's annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised upward by 60.98% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NBTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised upward by 60.98%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NBTX's stock price typically moves by 0% in the 10 days before its earnings and 0% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call summary indicates mixed sentiments. The basic financial performance and product development sections are promising with ongoing trials and potential partnerships, but uncertainties remain due to lack of specific guidance and unclear management responses. Financial health seems stable with disciplined capital allocation and a cash runway until 2028, but no clear shareholder return plan was mentioned. The Q&A highlighted uncertainties around trial outcomes and future guidance, balancing the positive aspects. Without a market cap, a neutral impact is predicted, with potential for volatility as trial results emerge.